About the Multiple Myeloma Session
Multiple myeloma, a type of cancer that affects plasma cells in bone marrow, has seen significant advancements in research. Scientists are delving into targeted therapies, such as proteasome inhibitors and immunomodulatory drugs, which disrupt cancer cell growth and enhance the immune system's ability to fight the disease. Additionally, monoclonal antibodies are being developed to specifically target myeloma cells, minimizing harm to healthy cells. Novel treatment approaches like CAR-T cell therapy hold promise, harnessing the body's immune cells to seek and destroy cancerous ones. Moreover, genetic profiling allows for personalized treatment strategies, optimizing outcomes for individual patients. With these multifaceted approaches, cancer researchers are making remarkable strides in improving survival rates and enhancing the quality of life for those battling multiple myeloma.
Topics Covered in Multiple Myeloma
Precursor Conditions
Cytogenetic Risk
Proteasome Inhibitors
BCMA-Targeted Therapy
Autologous Transplant
Lytic Bone Disease
Related Scientific Sessions at CIOC 2027
Why Attend the Multiple Myeloma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Multiple Myeloma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Multiple Myeloma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Multiple Myeloma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Multiple Myeloma Conference 2027 — FAQs
What is the Multiple Myeloma track at CIOC 2027?
The Multiple Myeloma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Multiple Myeloma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Multiple Myeloma sessions?
Cancer researchers and clinicians, educators and students with an interest in Multiple Myeloma are all welcome — whether presenting or attending.
Can I present my research in the Multiple Myeloma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Multiple Myeloma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Multiple Myeloma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.